Zhejiang Taimei Medical Technology Co., Ltd. (Taimei Tech, HKEX: 02576) disclosed that it bought back 72,400 H shares on 2 July 2026 through on-exchange transactions.
The repurchase was executed at prices between HKD 6.35 and HKD 6.67 per share, with a volume-weighted average cost of HKD 6.48. Total consideration reached HKD 0.47 million.
Key share capital movements: • Pre-transaction (30 June 2026): 199.28 million issued shares (excluding treasury) and 1.31 million treasury shares, for a total of 200.59 million. • Post-transaction (2 July 2026): 199.21 million issued shares (excluding treasury) and 1.38 million treasury shares, maintaining the total at 200.59 million. • Reduction in issued shares (excluding treasury): 72,400, equivalent to 0.04% of the pre-event share count.
Repurchase mandate utilisation: • Mandate approved on 23 June 2026, authorising buybacks of up to 20.02 million shares. • Cumulative repurchases under the mandate now stand at 960,200 shares, representing 0.48% of the issued share base at the mandate date.
All repurchased shares have been retained as treasury shares. Under exchange rules, Taimei Tech is restricted from issuing new shares or transferring treasury shares until 1 August 2026.